Address
304 North Cardinal
St. Dorchester Center, MA 02124
Work Hours
Monday to Friday: 7AM - 7PM
Weekend: 10AM - 5PM
Address
304 North Cardinal
St. Dorchester Center, MA 02124
Work Hours
Monday to Friday: 7AM - 7PM
Weekend: 10AM - 5PM
Product Name: Palbocent
Generic: Palbociclib
Indication : Hormone positive metastatic breast cancer
WhatsApp, WeChat, Telegram : +8801540071497
Scan the WeChat QR code to order now
The price of Palbocent 125 mg for 21 capsules is $120 in Bangladesh. Price is given in USD so that patients from everywhere understand the price and it may vary over the time. Onus pharma is a trusted supplier of palbocent globally. You can place your order now for this drug. To contact with us click the WhatsApp at the right bottom corner of the page.
Before buying this medicine make sure you are prescribed by Palbociclib 125 mg treat a specific type of breast cancer. Because this medicine is only available for prescribed patients. Palbocent is also popular in India, Pakistan, USA, Turkey and other country specially in the Asia pacific. Here are the price of India and Pakistan below. To know the price from other country contact with us.
In India Palbocent cost 10,000 INR, which can be changed any time. To know the exact price contact with us.
Palbocent 125 mg price in Pakistan is 33,000 Pakistani rupees.
Palbocent Capsule 125 mg is an initial treatment option for certain hormone receptor-positive and metastatic breast cancer in combination with other drug. It is also used to treat human epidermal growth factor receptor-2 (EFGR-2) negative metastatic breast cancer in combination with
It works by inhibiting cyclin-dependent kinase (CDK4/CDK6) protein. By blocking those protein it reduce the proliferation of cancer cells in patients and slowdown the cancer growth.
Each palbocent 125 mg contains active ingredients Palbociclib 125 mg.
General schedule of palbocent is daily once for first 21 days and then 28 days cycle. Palbocent is an oral medicine, patient can administrate this medicine with or without food according to doctor suggestion. General doses and modification are as follow
Patient should discontinue this medicine if they can not take 75 mg of palbocent daily. To change their dosage and administration, they must consult with their doctor. Exception administration may happen depending on patients situation.
Take the medicine as prescribed in the prescription. Do not take more or less of it, it can cause severe side effects. There are also other administration guide let’s have a look. Remember, these administration guides are only for general use. To know the exact administration ask your health care professional.
Precautions can save you from adverse side effects. You should take some precautions before you take Palbocent 125 mg to treat metastatic breast cancer locally or advanced.
Palboncent 125 is harmful to pregnant women, it is advised not to administrate palbocent in pregnant women. In case of breast feeding it is not recommended to take palbocent or to stop feeding breast.
Drug interaction can reduce the strength of the medicine or may cause serious side effects that can lead patients to the death. There are some drugs that can interact with sotorasib, that are mentioned below. There might be other drug that also interact with this drug, for more information ask your health care professionals.
Adverse side effects experienced by women are WBC decreased, Neutrophils decreased, Neutropenia, Platelets decreased, infections, AST increased, ALT increased, Leukopenia, Fatigue, Nausea, Hair loss, Inflammation of the mouth and lips, Diarrhea, Anemia, Rash, Weakness/lethargy, Vomiting, Thrombocytopenia, Dry skin, Fever.
Store it below 30 degree C, away from children and direct sunlight.
Do not take grape fruits or juice while taking palbocnet.
Do not take double dose if you miss your previous dose or do not miss next dose if you take an overdose. In case of overdose if any toxicity or change happen contact your doctor immediately.
Similar product Palboxen 125 mg, Palbonix 100 mg.
Reviews
There are no reviews yet.